Erika Hamilton, MD, is the director of breast cancer research at Sarah Cannon Research Institute.
New TROP2-Targeted ADC Shows Promise in TNBC: Erika Hamilton, MD
A new TROP2-targeted ADC showed promising efficacy in an early TNBC trial, with Erika Hamilton, MD, highlighting its potential for broader use in future treatment.